Literature DB >> 21448150

Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.

Allen M Spiegel, Steven K Libutti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21448150     DOI： 10.1038/nrclinonc.2011.50

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

Review 1.  Updates in pancreatic neuroendocrine carcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.

Authors:  Susan Alsamarai; Steven K Libutti; Muhammad Wasif Saif
Journal:  JOP       Date:  2010-07-05

2.  Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.

Authors:  A David McCollum; Matthew H Kulke; David P Ryan; Jeffrey W Clark; Lawrence N Shulman; Robert J Mayer; Sylvia Bartel; Charles S Fuchs
Journal:  Am J Clin Oncol       Date:  2004-10       Impact factor: 2.339

3.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

4.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

5.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1.

Authors:  H-C Jennifer Shen; Mei He; Anathea Powell; Asha Adem; Dominique Lorang; Charles Heller; Amelia C Grover; Kris Ylaya; Stephen M Hewitt; Stephen J Marx; Allen M Spiegel; Steven K Libutti
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

8.  Activity of sunitinib in patients with advanced neuroendocrine tumors.

Authors:  Matthew H Kulke; Heinz-Josef Lenz; Neal J Meropol; James Posey; David P Ryan; Joel Picus; Emily Bergsland; Keith Stuart; Lesley Tye; Xin Huang; Jim Z Li; Charles M Baum; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

Review 9.  Molecular basis for sunitinib efficacy and future clinical development.

Authors:  Sandrine Faivre; George Demetri; William Sargent; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694
  9 in total
  1 in total

1.  Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours.

Authors:  Steven K Libutti
Journal:  Nat Rev Endocrinol       Date:  2013-06-04       Impact factor: 43.330
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.